Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Initiating and continuing beta-blocker use in most first-time heart attack survivors for 20 years would result in 72,000 fewer coronary heart disease deaths, 62,000 fewer heart attacks, and 447,000 gained…  
  • “Although high cholesterol was recognized as a key risk factor for cardiovascular disease in the 1970s, there were no good ways to reduce it. The best drug available was…  
  • Antihypertensive therapy has been associated in clinical trials with a 1/3 reduction in stroke incidence, a 1/4 reduction in myocardical infarctions and a more than 1/2 reduction in heart failure.  
  • In 1996, fewer than 2 in 3 patients were receiving beta-blocker drugs to prevent a second heart attack. In 2006, more than 97% of heart attack patients received these treatments,…  
  • In 2005, approximately 469,000 coronary artery bypass procedures were performed on 261,000 patients in the U.S.